Furosemide

Frusemide Injection 10 mg per ml is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Frusemide Tablets 40 mg is an evidence-based cardiovascular and hemodynamic pharmaceutical formulation. It acts by modulating vascular smooth muscle tone, autonomic receptors, or fluid-electrolyte balance to manage cardiovascular disease.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Spironolactone is a synthetic steroid competitive mineralocorticoid receptor (aldosterone) antagonist and potassium-sparing diuretic on the WHO Model List of Essential Medicines. It blocks aldosterone binding in the late distal renal tubules and cortical collecting ducts, increasing sodium and water excretion while conserving potassium and hydrogen ions. In heart failure, it blocks aldosterone-mediated myocardial fibrosis and endothelial dysfunction. Indicated for heart failure with reduced ejection fraction (NYHA class II-IV), primary hyperaldosteronism, cirrhosis with ascites, resistant hypertension, and nephrotic edema.

Frusemide (40mg) and Amiloride (5mg) Tablets is a balanced loop and potassium-retaining diuretic combination on the WHO Model List of Essential Medicines. Frusemide exerts potent, rapid natriuresis in the loop of Henle, while amiloride blocks luminal epithelial sodium channels (ENaC) in the cortical collecting tubule, blunting potassium excretion without antiandrogenic hormonal effects. Indicated for congestive heart failure edema, hepatic cirrhosis with ascites, and nephrotic edema in patients prone to hypokalemia.

Frusemide (40mg) and Potassium Chloride Controlled Release (600mg CR) Tablets combines a high-ceiling loop diuretic with a potassium replenishment core. Frusemide induces significant renal loss of potassium and chloride alongside sodium and water; the controlled-release potassium chloride wax-matrix core dissolves gradually along the small intestine, replenishing potassium losses and preventing diuretic-induced hypokalemic metabolic alkalosis, muscle weakness, and cardiac dysrhythmias. Indicated for fluid overload in heart failure, nephrotic syndrome, and hepatic edema.